A Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2014
At a glance
- Drugs RG 3487 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Memory Pharmaceuticals
- 05 Dec 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
- 19 Nov 2008 Target accrual achieved; 212 patients randomised according to a Memory Pharmaceuticals media release.
- 26 Sep 2008 Added ref.